Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since May 26 · below the Ichimoku cloud · RSI 24 (oversold) · MACD below its signal · 3% above its 52-week low
None of the 29 investors followed here reported a position in UNCY in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a UNCY trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 24, 2025 | Aggarwal GauravDirector | — | 652.9K | — |
| Feb 17, 2025 | Aggarwal GauravDirector | — | 1.40M | — |
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Buy / hold / sell counts
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.5 | 16.1 | -5.1 | 16.4 | -3.7 | -36.4 | 6.8 | 3.8 | -9.7 | -21.1 | −35.8% | ||
| 2025 | -22.7 | -10.4 | 4.5 | 13.4 | -10.1 | -18.6 | -9.0 | -3.5 | 4.1 | 8.9 | 36.2 | -10.8 | −27.3% |
| 2024 | 9.4 | 45.3 | 0.0 | -18.8 | -21.4 | -43.1 | -12.8 | -22.7 | 20.7 | 31.1 | 28.8 | 15.2 | −8.5% |
| 2023 | 3.7 | -7.7 | 306.2 | -38.1 | 2.7 | -4.1 | -8.6 | -34.8 | 12.7 | -33.7 | -11.9 | 72.9 | +60.7% |
| 2022 | -33.0 | 0.7 | -7.2 | -32.5 | 2.2 | -6.7 | -10.8 | -5.4 | -15.7 | 16.9 | 3.2 | -24.2 | −73.8% |
| 2021 | 5.1 | -2.4 | 2.1 | -26.0 | -3.7 | −25.4% |